Close Menu

NEW YORK (360Dx) – Genomica and HuaSin on Monday announced that they have entered an agreement by which HuaSin obtained exclusive rights to develop and produce a fully automated HPV genotyping assay platform that uses Genomica's technology.

Financial and other terms of the deal were not disclosed.

Guangzhou, China-based HuaSin has commenced a registration process with the China Food and Drug Administration, and subject to regulatory approval anticipates launching the platform in China in 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.